CTOs on the Move


 
Health for health. This describes Zilis. We are building the world`s finest health and wellness brand. Our expert team` headed by Derrick DeSilva` M.D.` brings the latest science to our Ambassadors and customers. We are also founded on the belief that all children deserve adequate nutrition. With every sale` we provide life saving nutrition to children in developing countries.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zilis.com
  • 415 US Highway 377 Street 2020
    Argyle, TX USA 76226
  • Phone: 214.705.3702

Executives

Name Title Contact Details

Similar Companies

Wish Recovery

Wish Recovery is a luxury rehab and detox facility in Los Angeles that offers personalized and comprehensive care for individuals struggling with alcohol and drug addiction.

Allegro Medical

Allegro Medical is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lutronic USA

Lutronic USA is a Princeton Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New York Health Care

New York Health Care, Inc. is a licensed home healthcare agency engaged primarily in supplying the services of paraprofessionals who provide a broad range of healthcare support services to patients in their homes. The Company operates 24 hours a day,

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.